InvestSMART

Island Pharmaceuticals Limited (ASX:ILA)

ALERT: Price-sensitive ASX Announcement for ILA
Current share price for ILA : $0.375 -0.05 (-11.76%)+
Announcement
Release
19 May 2026 8:44AM
Price at Release
$0.425
Full Release
download
Summary
Island Pharmaceuticals Limited has announced its expansion in the US biodefence ecosystem by appointing Mark Herzog as Senior Global Health Security Advisor, leveraging his extensive experience in biodefence policy and government contracting. The company is advancing its antiviral drug Galidesivir for treating Marburg Virus Disease under the FDA Animal Rule and is actively engaging in the Medical Countermeasures Coalition to enhance its strategic position for potential procurement and stockpiling opportunities. Island is also finalizing arrangements with US-based biocontainment facilities to commence clinical trials in the next quarter.
Key Points
  • Island Pharmaceuticals has expanded its engagement in the US biodefence sector.
  • Senior Global Health Security Advisor, Mark Herzog, has been appointed.
  • Mark Herzog has over 25 years of experience in biodefence and government contracting.
  • Herzog has a track record of securing over US$100m in government contracts.
  • Island Pharmaceuticals is advancing Galidesivir for Marburg Virus Disease under the FDA Animal Rule.
  • Island is involved in the Medical Countermeasures Coalition (MC2) working groups focused on R&D and stockpiling.
  • The company is in advanced negotiations with US BSL-4 biocontainment facilities for clinical trials.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.